Search results (1320)
« Back to PublicationsInvestigation of the safety, tolerability and pharmacokinetics of Prolarix (TM), which comprises the prodrug tretazicar and a novel synthetic cosubstrate, caricotamide, in patients with late stage cancers
Waterman SC. et al, (2006), ANNALS OF ONCOLOGY, 17, 49 - 49
Priming the 'soil' for breast cancer metastasis: the pre-metastatic niche.
Psaila B. et al, (2006), Breast Dis, 26, 65 - 74
Final clinical, pharmacokinetic and pharmacodynamic results of the phase I study of the novel poly(ADP-ribose)polymerase (PARP) inhibitor, AG014699, in combination with temozolomide.
Plummer R. et al, (2005), CLINICAL CANCER RESEARCH, 11, 9099S - 9099S
Epoetin alfa: basic biology and clinical utility in cancer patients.
Littlewood T. and Collins G., (2005), Expert Rev Anticancer Ther, 5, 947 - 956
The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer.
Madhusudan S. and Middleton MR., (2005), Cancer Treat Rev, 31, 603 - 617
The safety and feasibility of extracorporeal high-intensity focused ultrasound (HIFU) for the treatment of liver and kidney tumours in a Western population.
Illing RO. et al, (2005), Br J Cancer, 93, 890 - 895
Two randomised phase II trials of subcutaneous interleukin-2 and histamine dihydrochloride in patients with metastatic renal cell carcinoma.
Donskov F. et al, (2005), Br J Cancer, 93, 757 - 762
First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors.
Plummer R. et al, (2005), J Clin Oncol, 23
First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors.
Plummer R. et al, (2005), JOURNAL OF CLINICAL ONCOLOGY, 23, 208S - 208S
Phase I study of GW572016 (lapatinib), a dual kinase inhibitor, in combination with irinotecan (IR), 5-fluorouracil (FU) and leucovorin (LV).
Midgley R. et al, (2005), JOURNAL OF CLINICAL ONCOLOGY, 23, 213S - 213S
The use of pharmacokinetic and pharmacodynamic endpoints to determine dose of AQ4N given with radiotherapy (RT).
Benghiat A. et al, (2005), J Clin Oncol, 23
The use of pharmacokinetic and pharmacodynamic endpoints to determine dose of AQ4N given with radiotherapy (RT).
Benghiat A. et al, (2005), JOURNAL OF CLINICAL ONCOLOGY, 23, 150S - 150S
Drugging cell cycle kinases in cancer therapy.
Blagden S. and de Bono J., (2005), Curr Drug Targets, 6, 325 - 335
Docetaxel in the management of ovarian cancer.
Blagden SP. and Kaye SB., (2005), Expert Rev Anticancer Ther, 5, 203 - 214
Optimising the use of arsenic trioxide in 'high risk' acute promyelocytic leukaemia (APL): The UK experience
Grimwade D. et al, (2005), BRITISH JOURNAL OF HAEMATOLOGY, 129, 28 - 28
Preliminary experience using extracorporeal high-intensity focused ultrasound for the treatment of kidney and liver tumours
Illing RO. et al, (2005), AIP Conference Proceedings, 754, 13 - 16
Temozolomide in the treatment of solid tumours: current results and rationale for dosing/scheduling.
Payne MJ. et al, (2005), Crit Rev Oncol Hematol, 53, 241 - 252
Temozolomide in the treatment of solid tumours: current results and rationale for dosing/scheduling
Payne MJ. et al, (2005), CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 53, 241 - 252